OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Rational Design of Novel Anticancer Small-Molecule RNA m6A Demethylase ALKBH5 Inhibitors
Simona Selberg, Neinar Seli, Esko Kankuri, et al.
ACS Omega (2021) Vol. 6, Iss. 20, pp. 13310-13320
Open Access | Times Cited: 90
Simona Selberg, Neinar Seli, Esko Kankuri, et al.
ACS Omega (2021) Vol. 6, Iss. 20, pp. 13310-13320
Open Access | Times Cited: 90
Showing 1-25 of 90 citing articles:
m6A modification: recent advances, anticancer targeted drug discovery and beyond
Lijuan Deng, Wei-Qing Deng, Shu-Ran Fan, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 257
Lijuan Deng, Wei-Qing Deng, Shu-Ran Fan, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 257
The roles and implications of RNA m6A modification in cancer
Xiaolan Deng, Ying Qing, David Horne, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 8, pp. 507-526
Closed Access | Times Cited: 172
Xiaolan Deng, Ying Qing, David Horne, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 8, pp. 507-526
Closed Access | Times Cited: 172
Targeting the RNA m6A modification for cancer immunotherapy
Xinxin Li, Shoubao Ma, Youcai Deng, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 149
Xinxin Li, Shoubao Ma, Youcai Deng, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 149
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Jing Yang, Jin Xu, Wei Wang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 143
Jing Yang, Jin Xu, Wei Wang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 143
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential
Jianwei Qu, Haimeng Yan, Yifan Hou, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 141
Jianwei Qu, Haimeng Yan, Yifan Hou, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 141
RNA-binding proteins and cancer metastasis
Shengjie Wang, Zelong Sun, Zhe Lei, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 748-768
Closed Access | Times Cited: 96
Shengjie Wang, Zelong Sun, Zhe Lei, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 748-768
Closed Access | Times Cited: 96
Genetic and epigenetic defects of the RNA modification machinery in cancer
Ines Oršolić, Arnaud Carrier, Manel Esteller
Trends in Genetics (2022) Vol. 39, Iss. 1, pp. 74-88
Open Access | Times Cited: 76
Ines Oršolić, Arnaud Carrier, Manel Esteller
Trends in Genetics (2022) Vol. 39, Iss. 1, pp. 74-88
Open Access | Times Cited: 76
METTL3 from Target Validation to the First Small-Molecule Inhibitors: A Medicinal Chemistry Journey
Francesco Fiorentino, Martina Menna, Dante Rotili, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 1654-1677
Open Access | Times Cited: 54
Francesco Fiorentino, Martina Menna, Dante Rotili, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 1654-1677
Open Access | Times Cited: 54
RNA modifications in cellular metabolism: implications for metabolism-targeted therapy and immunotherapy
Weiwei Liu, Si-Qing Zheng, Li Tian, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 32
Weiwei Liu, Si-Qing Zheng, Li Tian, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 32
Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 24
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 24
m6A Modification: A Double-Edged Sword in Tumor Development
Runnan Gao, Mujie Ye, Baihui Liu, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 63
Runnan Gao, Mujie Ye, Baihui Liu, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 63
Roles of RNA Modifications in Diverse Cellular Functions
Emma Wilkinson, Yan‐Hong Cui, Yu‐Ying He
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 56
Emma Wilkinson, Yan‐Hong Cui, Yu‐Ying He
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 56
Recent Advances of m6A Demethylases Inhibitors and Their Biological Functions in Human Diseases
Ya-Zhen You, Yun-Dong Fu, Ming-Jie Huang, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5815-5815
Open Access | Times Cited: 49
Ya-Zhen You, Yun-Dong Fu, Ming-Jie Huang, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5815-5815
Open Access | Times Cited: 49
Mechanisms of substrate recognition and N6-methyladenosine demethylation revealed by crystal structures of ALKBH5–RNA complexes
Simranjeet Kaur, Nok Yin Tam, M.A. McDonough, et al.
Nucleic Acids Research (2022) Vol. 50, Iss. 7, pp. 4148-4160
Open Access | Times Cited: 48
Simranjeet Kaur, Nok Yin Tam, M.A. McDonough, et al.
Nucleic Acids Research (2022) Vol. 50, Iss. 7, pp. 4148-4160
Open Access | Times Cited: 48
Discovery of two novel ALKBH5 selective inhibitors that exhibit uncompetitive or competitive type and suppress the growth activity of glioblastoma multiforme
Hikaru Takahashi, Hiroaki Hase, Takuya Yoshida, et al.
Chemical Biology & Drug Design (2022) Vol. 100, Iss. 1, pp. 1-12
Closed Access | Times Cited: 43
Hikaru Takahashi, Hiroaki Hase, Takuya Yoshida, et al.
Chemical Biology & Drug Design (2022) Vol. 100, Iss. 1, pp. 1-12
Closed Access | Times Cited: 43
Discovery of a potent, selective and cell active inhibitor of m6A demethylase ALKBH5
Zhen Fang, Bo Mu, Yang Liu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114446-114446
Closed Access | Times Cited: 39
Zhen Fang, Bo Mu, Yang Liu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114446-114446
Closed Access | Times Cited: 39
Advances in targeting RNA modifications for anticancer therapy
Monica Pomaville, Chuan He
Trends in cancer (2023) Vol. 9, Iss. 7, pp. 528-542
Open Access | Times Cited: 29
Monica Pomaville, Chuan He
Trends in cancer (2023) Vol. 9, Iss. 7, pp. 528-542
Open Access | Times Cited: 29
EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma
Deguan Lv, Cuiqing Zhong, Deobrat Dixit, et al.
Molecular Cell (2023) Vol. 83, Iss. 23, pp. 4334-4351.e7
Closed Access | Times Cited: 28
Deguan Lv, Cuiqing Zhong, Deobrat Dixit, et al.
Molecular Cell (2023) Vol. 83, Iss. 23, pp. 4334-4351.e7
Closed Access | Times Cited: 28
The potential role of m6A modifications on immune cells and immunotherapy
Linchuan Gan, Yuxiang Zhao, Yajuan Fu, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 160, pp. 114343-114343
Open Access | Times Cited: 26
Linchuan Gan, Yuxiang Zhao, Yajuan Fu, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 160, pp. 114343-114343
Open Access | Times Cited: 26
Discovery of Pyrazolo[1,5-a]pyrimidine Derivative as a Novel and Selective ALKBH5 Inhibitor for the Treatment of AML
Yingzhe Wang, Hongyu Li, Yan Zhang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 23, pp. 15944-15959
Closed Access | Times Cited: 22
Yingzhe Wang, Hongyu Li, Yan Zhang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 23, pp. 15944-15959
Closed Access | Times Cited: 22
A covalent compound selectively inhibits RNA demethylase ALKBH5 rather than FTO
Gan-qiang Lai, Yali Li, Heping Zhu, et al.
RSC Chemical Biology (2024) Vol. 5, Iss. 4, pp. 335-343
Open Access | Times Cited: 14
Gan-qiang Lai, Yali Li, Heping Zhu, et al.
RSC Chemical Biology (2024) Vol. 5, Iss. 4, pp. 335-343
Open Access | Times Cited: 14
Small molecule inhibitors targeting m6A regulators
Guotai Feng, Yongya Wu, Yuan Hu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 12
Guotai Feng, Yongya Wu, Yuan Hu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 12
RNA methylation‐related inhibitors: Biological basis and therapeutic potential for cancer therapy
Huanxiang Chen, Hongyang Liu, Chenxing Zhang, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 4
Open Access | Times Cited: 8
Huanxiang Chen, Hongyang Liu, Chenxing Zhang, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 4
Open Access | Times Cited: 8
Epigenetic Targets and Their Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
Xiaohui Miao, Pan Liu, Yangyang Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117463-117463
Closed Access | Times Cited: 1
Xiaohui Miao, Pan Liu, Yangyang Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117463-117463
Closed Access | Times Cited: 1
Zhaotong Wang, Jiawang Zhou, Haisheng Zhang, et al.
Molecular Oncology (2022) Vol. 17, Iss. 2, pp. 195-229
Open Access | Times Cited: 28
